News and Publications
News and Publications

Press Releases

03/02/15 Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing •>>
11/14/14 Vascular Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial of VPI-2690B for Diabetic Nephropathy •>>
09/12/12 Vascular Pharmaceuticals, Inc. Completes $16 Million Equity Financing, Signs Agreement with Janssen Biotech, Inc. •>>


Maile LA, Gollahon K, Wai C, Dunbar P, Busby W, Clemmons D. Blocking αVß3 Integrin Ligand Occupancy Inhibits the Progression of Albuminuria in Diabetic Rats. J Diabetes Res. 2014;2014:421827. Epub 2014 Oct 20.

Maile LA, Busby WH, Gollahon KA, Flowers W, Garbacik N, Garbacik S, Stewart K, Nichols T, Bellinger D, Patel A, Dunbar P, Medlin M, Clemmons D. Blocking Ligand Occupancy of the αVß3 Integrin Inhibits the Development of Nephropathy in Diabetic Pigs. Endocrinology. 2014 Aug 29:en20141318. [Epub ahead of print] PMID:25171599.

Clemmons D, Maile L, Xi G, Shen X, Radhakrishnan Y. Igf-I signaling in response to hyperglycemia and the development of diabetic complications. Curr Diabetes Rev. 2011 Jul;7(4):235-45. Review.

Maile LA, Walker H Busby, Timothy C Nichols*, Dwight A. Bellinger**, Elizabeth P. Merricks*, Michael Rowland, Umadevi Veluvolu and David R Clemmons. A novel anti-aVb3 integrin antibody inhibits IGF-I signaling and atherosclerotic lesion development in a porcine model of diabetes accelerated atherosclerosis. Science Translational Medicine 2010 Feb 10;2(18):18ra11.

Clemmons, DR, Maile, LA, Ling, Y, Yarber, J, Busby, WH. Role of the aVb3 in mediating increased smooth muscle Cell responsiveness to IGF-I in response to hyperglycemia. Growth Horm and IGF Res. Aug 17 (4) 265-70. 2007.

Maile, LA, Capps, BE, Ling Y, Xi, G and Clemmons DR. Hyperglycemia alters the responsiveness of smooth muscle cells to IGF-I. Endocrinol. 148(5):2435-43, May 2007

Maile, LA, Busby, WH, Sitko, K, Capps, BE, Sergent, T, Badley-Clarke, J, Ling, Y and Clemmons DR. The heparin-binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol Endocrinol. 20(4):881-92, Apr 2006.

Maile, LA, Busby, WH Jr, Sitko, K, Capps, B, Badley-Clarke, J and Clemmons DR. IGF-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the beta3-subunit of alphaVbeta3. Mol Endocrinol. 20(2):405-13, Feb 2006.